BLTE Belite Bio, Inc
Price Chart
Executive Summary
Belite Bio reported preliminary 2025 financial results and provided a significant business update, including positive Phase 3 DRAGON trial data for tinlarebant in Stargardt disease, completion of a $402 million public offering, and advancement of key clinical trials. The company is on track to submit an NDA to the FDA in Q2 2026, marking a pivotal step toward potential approval of the first treatment for Stargardt disease.
Key Financial Metrics
Actionable Insight
The combination of clinical success, robust funding, and a clear regulatory path significantly de-risks the investment thesis. Traders should monitor the upcoming NDA submission in Q2 2026 and potential interim data from the PHOENIX trial in GA as next catalysts.
Key Facts
- Positive topline results from Phase 3 DRAGON trial: 35.7% reduction in macular lesion growth (p=0.0033) in Stargardt disease patients.
- Completed $402 million public offering, significantly strengthening the balance sheet.
- Cash and equivalents rose to $352.9 million as of December 31, 2025, from $31.7 million a year earlier.
- On track to submit NDA for tinlarebant in Q2 2026 based on DRAGON trial data.
- DRAGON II and PHOENIX Phase 3 trials fully enrolled, with data expected in the coming months.
- Net loss widened to $77.6 million in 2025 from $36.1 million in 2024, primarily due to higher R&D and G&A expenses.
Financial Impact
Cash position increased by over $321 million net of operations, driven by $402 million offering. R&D and SG&A expenses more than doubled, reflecting advanced clinical and commercial preparation activities.
Risk Factors
- Regulatory risk: FDA may require additional data or delay approval despite Breakthrough Therapy designation.
- Clinical risk: PHOENIX trial in geographic atrophy may not replicate DRAGON success.
- Market risk: High valuation ($7.1B market cap) implies significant near-term success; any delay or setback could trigger sharp downside.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3247158 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 20, 2026
25d ago
|
Press Release
| $143.36 $148.00 | ▲ +3.24% | ▲ +1.43% | $138.16 (−3.63%) |
|
Apr 21, 2026
7w ago
|
6-K
| $167.42 $158.27 | ▼ −5.47% | ▼ −5.52% | $138.16 (−17.48%) |
|
Apr 21, 2026
7w ago
|
Press Release
| $167.42 $158.27 | ▼ −5.47% | ▼ −5.52% | $138.16 (−17.48%) |
|
Apr 9, 2026
9w ago
|
Insider Cluster
| $181.17 $158.05 | ▲ +12.76% | ▲ +15.95% | $138.16 (+23.74%) |
|
Apr 9, 2026
9w ago
|
Insider Cluster
| $181.17 $158.05 | ▲ +12.76% | ▲ +15.95% | $138.16 (+23.74%) |
|
Mar 2, 2026
14w ago
|
Press Release
| $177.58 $179.12 | ▲ +0.87% | ▲ +2.07% | $138.16 (−22.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access